Business Description
AnaptysBio Inc
NAICS : 325412
SIC : 2834
ISIN : US0327241065
Compare
Compare
Traded in other countries / regions
ANAB.USAAN6.Germany0HFQ.UKANAB.Mexico IPO Date
2018-01-24Description
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 21.94 | |||||
| Equity-to-Asset | 0.2 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -0.12 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.07 | |||||
| Beneish M-Score | -1.05 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -38.6 | |||||
| 3-Year EBITDA Growth Rate | -99.4 | |||||
| 3-Year EPS without NRI Growth Rate | -99.6 | |||||
| 3-Year FCF Growth Rate | -103.1 | |||||
| 3-Year Book Growth Rate | -38.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.7 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.87 | |||||
| Quick Ratio | 10.87 | |||||
| Cash Ratio | 10.44 | |||||
| Days Sales Outstanding | 69.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.9 | |||||
| Shareholder Yield % | 9.24 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -915.5 | |||||
| Net Margin % | -953.66 | |||||
| FCF Margin % | -708.79 | |||||
| ROE % | -100.98 | |||||
| ROA % | -31.24 | |||||
| ROIC % | -158.68 | |||||
| ROC (Joel Greenblatt) % | -760.8 | |||||
| ROCE % | -29.84 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 30.9 | |||||
| PB Ratio | 6 | |||||
| Price-to-Tangible-Book | 6.01 | |||||
| EV-to-EBIT | -1.04 | |||||
| EV-to-EBITDA | -1.06 | |||||
| EV-to-Revenue | 8.83 | |||||
| EV-to-FCF | -1.3 | |||||
| Price-to-Net-Current-Asset-Value | 12.41 | |||||
| Price-to-Net-Cash | 19.86 | |||||
| Earnings Yield (Greenblatt) % | -96.12 | |||||
| FCF Yield % | -23.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AnaptysBio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 17.157 | ||
| EPS (TTM) ($) | -6.08 | ||
| Beta | -0.09 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 25.822 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 25.822 - 25.822 | ||
| Shares Outstanding (Mil) | 26.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AnaptysBio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AnaptysBio Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
AnaptysBio Inc Frequently Asked Questions
What is AnaptysBio Inc(LTS:0HFQ)'s stock price today?
The current price of LTS:0HFQ is $25.82. The 52 week high of LTS:0HFQ is $25.82 and 52 week low is $25.82.
When is next earnings date of AnaptysBio Inc(LTS:0HFQ)?
The next earnings date of AnaptysBio Inc(LTS:0HFQ) is 2024-05-10 Est..
Does AnaptysBio Inc(LTS:0HFQ) pay dividends? If so, how much?
AnaptysBio Inc(LTS:0HFQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers